Skip To Main Content
Allison DeAngelis on Muck Rack

Allison DeAngelis

Verified
  • Biotech Startups and Venture Capital Reporter, STAT
As seen in: STAT, MSN, MSN India, Business Insider, Scribd, Yahoo News, Yahoo Finance, Bizwomen, BostInno, Boston Business Journal, Columbus Business First and
Reporter covering biopharma startups and venture capital at @statnews. Formerly @thisisinsider and @bosbizjournal.

Get in touch with Allison

Contact Allison, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies

|
By Allison DeAngelis Verified
| EIN News
Georg SchettBoulevard Bio By Allison DeAngelis Aug. 12, 2026 Biotech Startups and Venture Capital Reporter Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.
Open in Who Shared Issue with article?

A new biotech startup tries to tackle obesity, but not in the way you might expect

|
By Allison DeAngelis Verified
| EIN News
Mwyngil — pronounced “mwin-gull” — is studying ways to spur weight loss without targeting the GLP-1 receptor. That’s what attracted CEO Luba Greenwood, a biotech veteran, to the company. “I was not interested in another ‘me too’ GLP-1, or GLP-1 plus something. … That’s not very interesting science,” she told STAT, in her first interview about the company. The first two drug candidates will move into clinical trials by the end of this year, Greenwood said.
Open in Who Shared View Duplicates (3) Issue with article?

Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms

|
By Allison DeAngelis Verified
| EIN News
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder, the companies announced Monday.
Open in Who Shared View Duplicates (4) Issue with article?
See all 1,553 licensed articles (2,211 Total)